FDAnews Drug Daily Bulletin
Pharmaceuticals / Quality

Senator Slams FDA for Slow Approach to Oxilofrine in Supplements

April 15, 2016

Sen. Claire McCaskill (D-Mo.) is taking the FDA to task for its delayed reaction in targeting companies marketing supplements containing oxilofrine, a stimulant banned by the World Anti-Doping Agency for athletes.

McCaskill, ranking member of the Special Committee on Aging, cites a Harvard report that found at least 14 dietary supplements sold in the U.S. contain oxilofrine. Of those, 43 percent tested positive for pharmaceutical-grade levels of the substance.

Despite recently issuing seven warning letters to manufacturers for adding the stimulant to supplements, the senator calls the agency’s actions “troubling” for only taking action against three of the 14 supplements noted in the Harvard report.